Every year, millions of patients are trapped by wounds that simply refuse to close. Diabetic foot ulcers, pressure sores, venous leg ulcers, and severe burns share a sinister common thread: inflammation that never switches off. Now a comprehensive review published in Molecular Biology Reports argues that the key to predicting and ultimately preventing these chronic wounds may lie in a set of molecular machines called inflammasomes, whose fingerprints in wounded tissue could serve as powerful biomarkers for how a wound will behave.
The review, led by Rahul A. Sachdeo of Krishna Institute of Medical Sciences in Karad, India, together with colleagues from Krishna Institute of Pharmacy and the Gaurishankar Institute of Pharmaceutical Education and Research, weaves together decades of immunology research into a single framework. Its central claim is provocative: the same inflammasome complexes that protect us in the first hours after injury can, when they stay active too long, drive the persistent inflammation, tissue destruction, and scarring that turn an ordinary wound into a lifelong medical problem.
Inflammasomes are multi-protein sensors of the innate immune system, the body’s ancient first line of defense. Several family members matter in wounded skin, including NLRP3, AIM2, NLRC4, NLRP1, and Pyrin. Each sensor detects a different danger signal, from bacterial molecules to stray DNA released by damaged cells. Once triggered, an inflammasome assembles into an activation platform that switches on inflammatory caspases, most notably caspase-1. Caspase-1 then performs two critical tasks: it cleaves the inactive precursor forms of the signaling molecules interleukin-1 beta and interleukin-18 into their mature, biologically active versions, and it promotes a fiery form of programmed cell death called pyroptosis, which proceeds through pores formed by the protein gasdermin D.
In the short term, this machinery is lifesaving. Pyroptosis flushes intracellular pathogens out of infected cells, mature interleukin-1 beta recruits immune cells to clear debris and fight infection, and the resulting inflammatory signals help coordinate the earliest phases of tissue repair. Wound healing itself is a highly choreographed sequence of four overlapping stages: hemostasis, inflammation, proliferation, and remodeling. Transient inflammasome activity is what allows the wound to transition smoothly from the inflammatory phase into the proliferative phase, when new tissue is built. The trouble begins when the switch never gets flipped off.
Sustained or dysregulated inflammasome activation keeps caspase-1 running and pyroptosis churning, flooding the wound environment with inflammatory cytokines and cell contents. The result is persistent inflammation, ongoing tissue injury, and aberrant remodeling of the extracellular matrix, the protein scaffold that gives tissue its structure. Over time, this chaotic environment pushes the wound toward fibrosis, an excessive deposition of scar-like matrix, and toward the chronic wound state in which regeneration grinds to a halt. The review emphasizes that distinguishing inflammasome molecules’ roles as mechanistic mediators of this damage from their potential as measurable biomarkers and therapeutic targets is now a central task for the field.
What makes the review timely is its focus on specific molecular fingerprints. The authors catalog a broad panel of candidate biomarkers spanning the entire inflammasome pathway: the sensors themselves, the adaptor proteins that link them to caspases, the inflammatory caspases, pyroptosis-related mediators such as gasdermin D, the cytokines they release, and oxidative stress-associated factors. Oxidative stress is deeply entangled with inflammasome biology, since reactive oxygen species are known to regulate NLRP-family sensors, creating a crosstalk loop in which metabolic and inflammatory signals amplify one another. Molecules such as thioredoxin-interacting protein, which links high glucose to NLRP3 activation, illustrate how metabolic dysfunction can be read out through inflammasome-associated markers.
The review also highlights how modern genomic technologies are transforming biomarker discovery. Transcriptomic, proteomic, and metabolomic approaches can identify candidate molecules at scale, while single-cell RNA sequencing and spatial transcriptomics add two crucial dimensions: which cells are producing the signal, and where in the wound they are located. This cell-specific and spatial information matters enormously in wounds, where keratinocytes, macrophages, and fibroblasts exchange signals across a heterogeneous landscape. Recent work showing that diabetic wound keratinocytes can induce macrophage NLRP3 expression through interleukin-1 receptor signaling, and that interferon-gamma priming enables NLRP3 activation in human keratinocytes, underscores how cell-type-specific these interactions are. Such resolution, the authors argue, can improve biomarker validation and allow clinicians to stratify wound states far more precisely than current visual assessment allows.
One of the review’s most clinically valuable contributions is its comparison across wound types. Diabetic foot ulcers, pressure ulcers, venous leg ulcers, burn wounds, and fibrotic scars all involve inflammasome-mediated mechanisms, but each is driven by a distinct trigger. In diabetes, metabolic dysfunction and high glucose drive NLRP3 activation; in pressure ulcers, ischemia-reperfusion injury generates oxidative stress that aggravates tissue damage; in venous leg ulcers, venous hypertension sustains inflammatory pressure on the tissue; in burns, thermal injury releases damage-associated molecular patterns that activate inflammasomes, and studies in mouse models suggest NLRP3 activity is actually required for healing after burns; and in fibrotic scars, dysregulated tissue remodeling, often intertwined with transforming growth factor beta signaling, locks the wound into a scar-producing program. Understanding these shared and condition-specific pathways could allow therapies to be tailored to the biology of each wound rather than applied generically.
The therapeutic implications are already taking shape. Small-molecule NLRP3 inhibitors, first validated as potential treatments for inflammatory diseases, are being explored for diabetic wounds, and nanotechnology-based delivery systems and stimulus-responsive hydrogels are being designed to modulate inflammasome activity directly at the wound site. Meanwhile, smart wound dressings that monitor biological parameters in real time could eventually incorporate inflammasome-derived markers, turning a passive bandage into a diagnostic device. Cytokine ratios measured in chronic wound swabs, such as interleukin-1 beta relative to its natural antagonist the interleukin-1 receptor antagonist, have already been proposed as potential biomarkers of wound healing stage and infection status, hinting that the clinic may not be far behind the laboratory.
Challenges remain before inflammasome biomarkers reach the bedside. Inflammasome activation is context-dependent, and a marker that signals danger in one wound type may signal productive repair in another, as the burn studies suggest. Validation will require large, well-characterized patient cohorts and multi-omic profiling across wound types and healing stages. Yet the framework laid out in this review offers something chronic wound medicine has lacked: a mechanistic, measurable, and spatially resolved language for describing why some wounds heal and others stall. If that language can be translated into routine diagnostics, the millions of patients caught in the cycle of chronic inflammation and scarring may finally get the precision care their wounds demand.
Subject of Research: The role of inflammasome-derived biomarkers in wound healing, chronic inflammation, fibrosis, and precision therapeutics
Article Title: Inflammasome-derived biomarkers in wound healing: linking tissue repair, chronic inflammation, fibrosis, and precision therapeutics
Article References: Sachdeo, R. A., Khanwelkar, C., Shete, A., Patil, S. J., & Pawar, N. B. (2026). Inflammasome-derived biomarkers in wound healing: linking tissue repair, chronic inflammation, fibrosis, and precision therapeutics. Molecular Biology Reports, 53(1), Article 1610. https://doi.org/10.1007/s11033-026-12783-x
Image Credits: AI Generated
DOI: 10.1007/s11033-026-12783-x
Keywords: inflammasome, NLRP3, wound healing, chronic wounds, pyroptosis, biomarkers, fibrosis, caspase-1, diabetic foot ulcers, interleukin-1 beta, single-cell RNA sequencing, precision medicine
News Source: Juliet Wilcox. (October 14, 2026). Inflammasome Biomarkers Could Predict Which Wounds Heal and Which Turn Chronic. Scienmag.
